GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

Duodenal gastrointestinal stromal tumors (DGISTs) represent a rare subset of mesenchymal neoplasms of the gastrointestinal tract, accounting for approximately 3–5% of all gastrointestinal stromal ...

Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...

These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations. Unfavorable trends in the diagnosis ...

Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development of resistance, and worse overall survival (OS), a ...

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression and ...

Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk stage II-III gastrointestinal stromal tumor. This is an ASCO Meeting Abstract from ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...